過去觀察性的研究發現，早產兒開放性動脈導管(patent ductus arteriosus, PDA)與早產兒慢性肺疾病、壞死性腸炎、腦室內出血、神經發育結果不佳以及死亡率風險的增加是有關聯的。靜脈注射indomethacin或ibuprofen常用於治療早產兒開放性動脈導管。不過靜脈注射indomethacin可能會導致腎功能障礙、腸炎、腦室內出血。而靜脈注射ibuprofen目前被證明也是有效的，引起的副作用較少；但因ibuprofen針劑在國內未核可上市（無許可證），需向衛生署報備請廠商專案進口，所以若能有其他更方便取得的藥物，將對治療有很大的幫助。口服ibuprofen懸液劑是小兒常用藥物，所含成分與靜脈注射ibuprofen相同；本文提供了兩個出生體重低下之早產兒，使用口服ibuprofen懸液劑治療開放性動脈導管的案例，並進行文獻回顧，評估使用口服ibuprofen懸液劑治療早產兒開放性動脈導管的可行性，希望能提供另一種治療參考。
 

Observational studies have suggested an association between clinically patent ductus arteriosus (PDA) in preterm infants and increased risk of chronic lung disease (CLD), necrotising enterocolitis (NEC), intraventricular haemorrhage (IVH), poor neurodevelopmental outcome and mortality. Intravenous indomethacin and intravenous ibuprofen are widely used for the treatment of PDA in premature infants. Intravenous indomethacin may lead to renal impairment, NEC, and IVH. Intravenous ibuprofen was shown to be as effective and to cause fewer side effects. However, the intravenous form of ibuprofen is not approval and available easily in Taiwan, whereas, the oral suspension form is widely used for antipyretic treatment in children. Therefore, we provide two prematurity newborns with very low birth weights, who received oral ibuprofen suspension for PDA treatment, and literatures review in order to evaluate the feasibility of the use oral ibuprofen suspension in the treatment of PDA in premature infants for medical staffs.